BioCentury
ARTICLE | Finance

Naurex Nyxis the Past

Naurex gets $18M from VCs plus Lundbeck, Takeda, Shire to fund depression drug

May 16, 2011 7:00 AM UTC

Naurex Inc., a restart neurology play, has raised $18 million in a series A round from a syndicate that includes three strategic investors.

The round was led by Adams Street Partners. The other investors included Latterell Venture Partners. Druid BioVentures; Genesys Capital; PathoCapital; H. Lundbeck A/S (CSE:LUN); Takeda Ventures; and Shire plc (LSE:SHP; NASDAQ:SHPGY)...